AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ — Equity Insider News Commentary – Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery market at approximately $1.71 billion in 2024 and projects it will reach roughly $8.52 billion by 2030, a compound annual growth rate of about 30.58%. That is a market compounding at more than double the rate of most enterprise software categories, and it is being spent inside an industry that already invests over $250 billion a year in research and development. The question the forecast does not answer is where the durable value in that spend actually accrues.

Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (Nasdaq: HYFT), Tempus AI, Inc. (Nasdaq: TEM), Schrödinger, Inc. (Nasdaq: SDGR), Twist Bioscience Corporation (Nasdaq: TWST), Absci Corporation (Nasdaq: ABSI).

Forecasters size the category differently but point the same direction. Grand View Research estimated the same market at approximately $1.49 billion in 2023 and projects roughly $9.17 billion by 2030 at a compound annual growth rate of about 29.6%. The variance between houses is largely a question of what counts as an AI drug discovery product and what counts as the data plumbing underneath it. That distinction is not a rounding error. It is the whole argument.

Models have become the cheap part. Foundation models are released, licensed, fine-tuned and superseded on a cycle now measured in months, and a discovery team that standardised on one architecture two years ago has almost certainly replaced it. Nothing about that cycle is a durable competitive position. Anything a laboratory can rent from three vendors is not an advantage, it is a cost line.

What has not become cheap is context. Discovery data arrives fragmented by design: sequences in one system, structures in another, assay outputs, omics, literature, provenance and program history scattered across the rest, much of it recorded in formats chosen by whoever ran the experiment. A model pointed at that estate is reasoning over isolated files rather than over connected biology. Worse, the most expensive information a pharmaceutical company owns, the record of what failed and why, is usually the least well preserved.

That has pushed attention toward the layer beneath the models, and toward the same structural question the rest of the AI economy has been working through. In compute the constraint turned out to be power. In life sciences the constraint is proving to be governed, connected, machine-readable biological context, and it is a constraint that cannot be closed by licensing a better model.

MindWalk Holdings Corp. (Nasdaq: HYFT) Reports Fiscal 2026 Revenue Up 46% and Launches ReefIQ™ Biological Context Layer

– Fiscal 2026 revenue of C$15.6 million, up 46% from C$10.6 million.

– Gross margin expanded to 58.8% from 53.9%; net loss from continuing operations narrowed by more than half.

– First two contracted, recurring platform agreements signed during the year.

– ReefIQ™ launched June 10, 2026 as the biological context layer built on HYFT® Technology.

– Regained Nasdaq listing compliance without a reverse split, and added to the Russell 3000E and Russell Microcap Indexes.

MindWalk Holdings Corp. (Nasdaq: HYFT) is a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require. Its proprietary HYFT® Technology powers a function-aware representation of biology organized around HYFT pattern-objects spanning sequence and structural biology, refined over twenty years of curation into a continuously evolving biological representation of 660 million biological patterns and 25 billion relationships that enriches data at ingestion and compounds in analytical value with every program run on the platform.

The architecture resolves into three layers that stack rather than compete. HYFT® Technology powers the biological representation. ReefIQ™, launched June 10, 2026, is the biological context layer: it harmonizes a client’s discovery data, links it to MindWalk’s biological representation foundation, preserves provenance and program history, and exposes governed, queryable context. LensAI™ is the reasoning and application layer, operating on that context to support retrieval, analysis, target discovery, candidate diligence, hypothesis generation and portfolio decision support, and to host the agentic AI workflows pharma is racing to deploy. LensAI is already in contracted, recurring arrangements with life-sciences customers today.

“In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over. Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost. ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic,” said Dr. Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp.

The fiscal year ended April 30, 2026 was the first in which the commercial argument showed up in reported results. Revenue grew 46% to C$15.6 million from C$10.6 million, gross margin expanded to 58.8% from 53.9%, and net loss from continuing operations narrowed by more than half. The company divested its Netherlands subsidiary, completed its rebranding from ImmunoPrecise Antibodies Ltd., regained Nasdaq listing compliance organically without a reverse split or dilution, and was subsequently added to the Russell 3000E and Russell Microcap Indexes. Results and filings are available through the company’s investor relations newsroom and on EDGAR.

Two developments since year-end frame where the platform is heading. The company filed a European patent application covering high-dimensional data structures for biological subsequences and property inference, building on its foundational HYFT patent estate. And on July 23, 2026, at AMD’s Advancing AI 2026 event in San Francisco, MindWalk presented the first public demonstration of ReefIQ™ running on AMD Instinct™ accelerators, which the company describes as memory-rich and open-stack. MindWalk participated as a selected featured exhibitor; that selection does not imply endorsement, sponsorship, partnership or any commercial relationship with AMD beyond the showcase itself.

There are several risks associated with the Company’s plans. MindWalk is a micro-cap company that remains unprofitable, and revenue is still primarily fee-for-service discovery work rather than recurring platform revenue, which management has described as modest and not yet significant to the fiscal 2026 total. The contracted, recurring arrangements referenced above are not quantified, and specific customers, deployment counts and contract values have not been disclosed. Operating expenses in the commercial organization rose during the year with no guidance provided on their trajectory, fourth quarter revenue came in below analyst estimates, and the shares traded lower after the print. The company reports in Canadian dollars and files as a foreign private issuer on Form 20-F. Readers should review the Company’s filings with the U.S. Securities and Exchange Commission and on SEDAR+ in full.

CONTINUED… Read this and more news for MindWalk Holdings Corp. (Nasdaq: HYFT) at: https://equity-insider.com

In other industry developments and happenings in the market this week include:

Tempus AI, Inc. (Nasdaq: TEM) sells precision-medicine diagnostics alongside a data licensing business that supplies pharmaceutical customers with multimodal clinical and molecular data, which makes it the closest large-scale public analogue to the argument that context, not models, is the asset. The company reported second quarter 2026 results with revenue of $382.5 million, up 22% year over year, Diagnostics contributing $289.3 million on 20% growth and Data and Applications $93.2 million on 28% growth.

Gross profit rose 26% to $246.5 million and the company recorded net income of $5.6 million against a net loss of $42.8 million a year earlier, with adjusted EBITDA of $8.0 million versus negative $5.6 million. Oncology volume grew 31% year over year and Data Licensing and Modeling revenue rose 36%. Founder and Chief Executive Officer Eric Lefkofsky described the quarter as exceptional and attributed it to investments made in AI over several years. Tempus is a materially larger business than most names in this cohort and is referenced for sector context rather than as a comparable.

Schrödinger, Inc. (Nasdaq: SDGR) takes the opposite technical route to the same problem, applying physics-based computational chemistry rather than pattern learning to molecular discovery. The company recently reported second quarter 2026 annual contract value of $29.6 million, representing 27% growth, and launched an early access version of Bunsen, described as an agentic AI co-scientist for molecular discovery.

Chief Executive Officer Ramy Farid stated that the results reflect growing industry adoption of a predict-first approach to molecular discovery, and that as biopharma navigates a rapidly evolving AI landscape and mounting pressure to accelerate discovery, the need to generate ground-truth data has never been greater. That last phrase is the point of contact with the broader thesis. Whether the ground truth is generated by simulation or preserved from prior programs, the constraint being described is the same one.

Twist Bioscience Corporation (Nasdaq: TWST) operates further down the stack again, manufacturing synthetic DNA and NGS tools that the discovery industry consumes as raw input. The company announced third quarter fiscal 2026 revenue of $118.4 million, growth of more than 23% year over year and its fourteenth consecutive quarter of growth, with gross margin of 52.8%, up sequentially from 51.6%. NGS Applications revenue grew 12% to $61.8 million.

Full-year fiscal 2026 revenue guidance was raised to a range of $456 million to $457 million, an increase of $12 million at the midpoint, and the company reiterated its expectation of adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. Chief Executive Officer and co-founder Emily M. Leproust said the company remains confident in its trajectory and added that the breakeven milestone is not the destination. Twist is a picks-and-shovels business rather than a software one, included here because the infrastructure-beneath-discovery argument runs through physical inputs as well as data.

Absci Corporation (Nasdaq: ABSI) designs biologics with generative AI and has been moving from a pure discovery platform toward clinical-stage development of its own therapeutics. In results reported August 11, 2026, the company posted second quarter revenue of $0.3 million against $0.6 million a year earlier, research and development expenses of $22.6 million versus $20.5 million, and a net loss of $33.2 million compared with $30.6 million.

Cash, cash equivalents and marketable securities stood at $201.1 million at June 30, 2026, up from $125.7 million at March 31, following a capital raise that included a $40 million strategic investment from Eli Lilly and extended runway into the second half of 2028. Founder and Chief Executive Officer Sean McClain pointed to positive Phase 1 interim data from the HEADLINE trial and to interim proof-of-concept data for pattern hair loss expected later this year, with a full 26-week readout in early 2027. Both revenue and loss per share came in below analyst estimates and the shares fell sharply in after-hours trading on the print, so the strengthened balance sheet and the quarterly numbers are telling different stories.

Contact Information:

https://equity-insider.com

Media Contact:
info@equity-insider.com

DISCLAIMER:

Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation, and no communication from us should be deemed personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are neither licensed nor qualified to provide investment advice. The material on this page is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform their own research and due diligence and to consult a licensed financial professional before considering any level of investing in stocks.

This article is being distributed for Market Equities Limited, a company incorporated under the laws of Ireland (“MEL”), which wholly owns and operates Equity Insider. MEL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group (“CDMG”). MEL has not been paid a fee directly by MindWalk Holdings Corp., and MEL is not affiliated with, and is a separate and independent entity from, CDMG and MindWalk Holdings Corp. MEL also expects to receive further compensation as part of an ongoing digital media effort to increase visibility for the company. No further notice will be given, but let this disclaimer serve as notice that all material, including this article, has been reviewed and approved by MindWalk Holdings Corp. and CDMG.

This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision.

MEL and its owner/operators do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of MindWalk Holdings Corp. and may liquidate their shares, which could have a negative effect on the price of the stock.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. Be extremely careful, investing in securities carries a high degree of risk; you may lose some or all of your investment. This document is governed by the laws of Ireland.

Cautionary Note Regarding Financial Information and Corporate History. MindWalk Holdings Corp. was formerly ImmunoPrecise Antibodies Ltd. and was renamed in September 2025. Financial figures presented in this article are as reported by the Company for the fiscal year ended April 30, 2026 and are stated in Canadian dollars unless otherwise noted. They are presented as reported by the Company and have not been independently verified by the publisher. The Company reports as a foreign private issuer on Form 20-F, which carries different periodic reporting obligations than those applying to a domestic United States filer. Filings are available on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca.

Cautionary Note Regarding Technology and Platform Claims. Descriptions of HYFT® Technology, ReefIQ™ and LensAI™, including pattern and relationship counts, curation history, product capabilities and the existence of contracted, recurring arrangements with life-sciences customers, are as described by the Company and have not been independently verified by the publisher. Those arrangements are not quantified, and specific customers, deployment counts and contract values have not been disclosed. Statements regarding platform adoption, commercial arrangements and future development are forward-looking and are not assurances of commercial outcomes. Patent applications are applications and may not be granted. Nothing in this article should be read as a claim of therapeutic benefit, efficacy or regulatory approval in respect of any product or program.

Cautionary Note Regarding Third-Party Technology References. References in this article to AMD, AMD Instinct or related architecture are paraphrased from public disclosures and are not product claims made by MindWalk Holdings Corp. MindWalk’s participation in the AMD Instinct demo showcase at Advancing AI 2026 was as a selected featured exhibitor. References to AMD do not imply endorsement, sponsorship, partnership or any commercial relationship beyond that selection.

Cautionary Note Regarding Referenced Companies. References to Tempus AI, Inc., Schrödinger, Inc., Twist Bioscience Corporation and Absci Corporation are provided solely as market and sector context. Those companies are not peers, competitors, or financial comparables of MindWalk Holdings Corp. They are at materially different stages of development and scale, and their results, revenues, contract values and share performance are not indicative of MindWalk Holdings Corp.’s prospects. None of those companies is involved in the production or distribution of this article. No partnership, affiliation, sponsorship, or endorsement is implied. Market-size figures cited in this article are third-party projections of total market value and do not represent addressable revenue for any company named, including the profiled company. Market data referenced in this article is supplied by third parties, is for informational purposes only, and may be delayed.

Trademarks. HYFT® is a registered trademark of MindWalk Holdings Corp. ReefIQ™ and LensAI™ are trademarks of MindWalk Holdings Corp. All other marks referenced in this article are the property of their respective owners.

Eagle Eye Disclosure. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision. See it at eagle-eye.dev.

Cautionary Note Regarding Forward-Looking Statements. This publication may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including projections of market size and growth, estimates of customer adoption, expectations regarding platform commercialization, contracted and recurring arrangements, patent prosecution, financial condition and management’s plans and objectives. Such statements are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “believes”, “intends”, “potential” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual circumstances, events, or results to differ materially, including competitive, technological, commercial, financing, dilution, listing and market risks, and other risks identified in the Company’s filings with the Securities and Exchange Commission at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Do not place undue reliance on such statements. The forward-looking statements in this publication are made as of the date above and Equity Insider undertakes no obligation to update them.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-in-drug-discovery-market-projected-to-reach-8-52-billion-by-2030–302868297.html

SOURCE Equity Insider